| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; dosing completion expected by mid-2027 |
| 06 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2026, and is entered into by and among ROCKET PHARMACEUTICALS, INC., a Delaware corporation (“Company”), its Subsidiaries SPACECRAFT SEVEN, LLC, a Delaware limited li... |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol |
| 27 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic microangiopathy, capillary leak syndrome, or other significant safety con... |
| 03 Aug 2026 |
8-K: Regulation FD Disclosure
Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observed |
| 30 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. |
| 12 Jun 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
CRANBURY, NJ – June 12, 2026 – Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today a... |
| 21 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 Annual Meeting of Stockholders of Rocket Pharmaceuticals, Inc. (the “Company”) was held on May 20, 2026 (the “Annual Meeting”). At the Annual Meeting, there were present, in person or by proxy, holders of 80,774,659 shares of co... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated |
| 28 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline |
| 27 Mar 2026 |
8-K: Regulation FD Disclosure
First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 |
| 10 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Rocket Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 |
| 14 Oct 2025 |
8-K: Other Events
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) |
| 03 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 03 Oct 2025 |
8-K: Other Events
On October 3, 2025, Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) reported that it has voluntarily withdrawn its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for mozafancogene autotemc... |
| 29 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. |
| 17 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
This letter (the “Agreement and Release”) confirms our agreement with regard to the resignation of your employment with Rocket Pharmaceuticals, Inc. (“the Company”) effective December 31, 2025 (the “Separation Date”). For avoidance of do... |
Loading...